Several companies, including GSK, Janssen, Novartis and Pfizer, have announced that they are cutting their pipelines as they release their full-year 2022 financial results. The following are the drugs removed from these companies’ pipelines. Bristol Myers Squibb Anti-CTLA-4 NF: The oncology monoclonal antibody candidate directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) known as BMS-986218 was…